Appili Therapeutics Inc. (APLIF)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 1.49 Million CAD | -82.0% |
| 2023 | 8.28 Million CAD | -54.79% |
| 2022 | 18.31 Million CAD | 63.93% |
| 2021 | 11.17 Million CAD | 63.48% |
| 2020 | 6.83 Million CAD | 0.0% |
| 2019 | 6.83 Million CAD | -4.95% |
| 2018 | 7.19 Million CAD | 180.06% |
| 2017 | 2.56 Million CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 7.13 Million CAD | -13.83% |
| 2024 Q2 | 3.9 Million CAD | -45.26% |
| 2024 FY | 1.49 Million CAD | -82.0% |
| 2024 Q4 | 1.49 Million CAD | -24.28% |
| 2024 Q3 | 1.96 Million CAD | -49.61% |
| 2023 Q1 | 7.13 Million CAD | -13.83% |
| 2023 Q3 | 2.58 Million CAD | -33.75% |
| 2023 Q4 | 8.28 Million CAD | 220.01% |
| 2023 Q2 | 3.9 Million CAD | -45.26% |
| 2023 FY | 8.28 Million CAD | -54.79% |
| 2022 Q2 | 11.89 Million CAD | -0.1% |
| 2022 Q1 | 11.9 Million CAD | -35.01% |
| 2022 FY | 18.31 Million CAD | 63.93% |
| 2022 Q4 | 8.28 Million CAD | -27.11% |
| 2022 Q3 | 11.36 Million CAD | -4.46% |
| 2021 Q2 | 23.72 Million CAD | -9.53% |
| 2021 FY | 11.17 Million CAD | 63.48% |
| 2021 Q4 | 18.31 Million CAD | -14.94% |
| 2021 Q1 | 26.22 Million CAD | 134.66% |
| 2021 Q3 | 21.53 Million CAD | -9.22% |
| 2020 FY | 6.83 Million CAD | 0.0% |
| 2020 Q3 | 3.05 Million CAD | -19.24% |
| 2020 Q2 | 3.78 Million CAD | -26.55% |
| 2020 Q1 | 5.15 Million CAD | -24.55% |
| 2020 Q4 | 11.17 Million CAD | 265.3% |
| 2019 Q4 | 6.83 Million CAD | 12.77% |
| 2019 Q3 | 6.06 Million CAD | 0.0% |
| 2019 FY | 6.83 Million CAD | -4.95% |
| 2019 Q1 | - CAD | -100.0% |
| 2018 Q4 | 7.19 Million CAD | 0.0% |
| 2018 FY | 7.19 Million CAD | 180.06% |
| 2017 FY | 2.56 Million CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 96.163% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 79.357% |
| SQZ Biotechnologies Company | 107.18 Million USD | 98.61% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 85.878% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 98.855% |
| Mesoblast Limited | 667.9 Million USD | 99.777% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -1959.563% |
| Genus plc | 1.02 Billion USD | 99.855% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -9.721% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -198.655% |
| Marizyme, Inc. | 22.01 Million USD | 93.23% |
| ContraFect Corporation | 20.67 Million USD | 92.793% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -137.704% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -281.796% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -289.977% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -4.076% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 64.052% |
| MultiCell Technologies, Inc. | 126.22 USD | -1180697.813% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -58.606% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 98.84% |
| EV Biologics, Inc. | 431.71 Thousand USD | -245.229% |
| Q BioMed Inc. | 3.51 Million USD | 57.605% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 95.763% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -93.397% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -470.43% |
| Biomind Labs Inc. | 73.81 Thousand USD | -1918.996% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 99.678% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 95.034% |
| Skye Bioscience, Inc. | 11.94 Million USD | 87.518% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 55.014% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 45.731% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 23.889% |
| IMV Inc. | 31.33 Million USD | 95.243% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -116.79% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 42.747% |
| GB Sciences, Inc. | 103.44 Thousand USD | -1340.81% |
| Alpha Cognition Inc. | 2.45 Million USD | 39.221% |
| HST Global, Inc. | 1526.00 USD | -97567.3% |
| CSL Limited | 38.02 Billion USD | 99.996% |
| Halberd Corporation | 10.13 Thousand USD | -14611.312% |
| Enzolytics Inc. | 361.7 Million USD | 99.588% |
| Resverlogix Corp. | 8.11 Million USD | 81.634% |
| Affymax, Inc. | 7.44 Million USD | 79.976% |
| SYBLEU INC | 330.46 Thousand USD | -350.998% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 20.634% |
| argenx SE | 4.54 Billion USD | 99.967% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 94.666% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 96.876% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -6442.307% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 83.346% |
| AVAX Technologies, Inc. | 7.37 Million USD | 79.797% |
| Zenith Capital Corp. | 7410.00 USD | -20013.401% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.956% |
| Ember Therapeutics, Inc. | 184.00 USD | -809901.63% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -363.137% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -470.24% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.666% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -2.868% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | 50.732% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 97.172% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -60.611% |
| BioStem Technologies, Inc. | 14.56 Million USD | 89.764% |
| ONE Bio Corp. | 70.08 Million USD | 97.873% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -2510.437% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -64419.61% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -50.856% |
| Agentix Corp. | 261.39 Thousand USD | -470.179% |
| LadRx Corporation | 2.3 Million USD | 35.421% |
| Cell Source, Inc. | 195.17 Thousand USD | -663.64% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -210.141% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -321.474% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -321.474% |
| NovAccess Global Inc. | 62.24 Thousand USD | -2294.299% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -133.001% |
| Itoco Inc. | 1.4 Million USD | -6.452% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -1458.07% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -1306.041% |
| Kadimastem Ltd | 2.3 Million USD | 35.315% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -1851.965% |
| CytoDyn Inc. | 11.13 Million USD | 86.616% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -942.444% |
| Mobile Lads Corp. | 52.00 USD | -2866059.615% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -8235.587% |
| Qrons Inc. | 420.00 USD | -354757.857% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -286.645% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -169.942% |
| Rebus Holdings, Inc. | 5000.00 USD | -29708.06% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -264.026% |
| International Stem Cell Corporation | 5.39 Million USD | 72.349% |
| Bioxytran, Inc. | 137.63 Thousand USD | -982.843% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 90.065% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 91.01% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -1786.586% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -72.365% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 80.173% |
| Neutra Corp. | 2851.00 USD | -52176.499% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 95.401% |
| PureTech Health plc | 693.97 Million USD | 99.785% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 81.534% |
| IXICO plc | 15.84 Million USD | 90.593% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 82.004% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.558% |
| CSL Limited | 38.02 Billion USD | 99.996% |
| Cellectis S.A. | 333.99 Million USD | 99.554% |